AVITA Medical Sees Prelim. Q3 Revenue $13.5M vs $13.45M Est.
Portfolio Pulse from Benzinga Newsdesk
AVITA Medical has reported preliminary Q3 revenue of $13.5M, slightly above the estimated $13.45M.
October 18, 2023 | 1:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AVITA Medical, listed as RCEL, reported Q3 revenue slightly above estimates, which may positively impact the stock.
AVITA Medical's Q3 revenue has exceeded estimates, which is generally seen as a positive sign by investors and could lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100